Gabreal Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 31 Year, 11 Months
- Last Filing with ROC 31 Mar 2024
- Satisfied Charges ₹ 0.48 M
- Revenue Growth -46.61%
- Profit Growth -13.07%
- Ebitda 187.93%
- Net Worth 1.61%
- Total Assets 7.92%
About Gabreal Pharmaceuticals
Gabreal Pharmaceuticals Pvt Ltd (GPPL) is a Private Limited Indian Non-Government Company incorporated in India on 04 March 1993 and has a history of 31 years and 11 months. Its registered office is in Thane, Maharashtra, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company has closed loans amounting to ₹0.48 M, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Arun Jategaonkar and Megha Jategaonkar serve as directors at the Company.
Company Details
- Location
Thane, Maharashtra, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U99999MH1993PTC071034
- Company No.
071034
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
04 Mar 1993
- Date of AGM
29 Aug 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Who are the key members and board of directors at Gabreal Pharmaceuticals?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Arun Jategaonkar  | Managing Director | 02-Jan-1998 | Current |
Board Members (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Megha Jategaonkar | Director | 04-Mar-1993 | Current |
Financial Performance of Gabreal Pharmaceuticals.
Gabreal Pharmaceuticals Pvt Ltd, for the financial year ended 2022, experienced significant reduction in revenue, with a 46.61% decrease. The company also saw a substantial fall in profitability, with a 13.07% decrease in profit. The company's net worth moved up by a moderate rise of 1.61%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Gabreal Pharmaceuticals?
In 2018, Gabreal Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹0
₹0.48 M
Charges Breakdown by Lending Institutions
- Dombivli Nagari Sahakari Bank Ltd. : 0.04 Cr
- Dombivli Nagrik Sahkari Bank Limited : 0.01 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 01 Aug 2013 | Dombivli Nagari Sahakari Bank Ltd. | ₹0.40 M | Satisfied |
| 16 Jul 1993 | Dombivli Nagrik Sahkari Bank Limited | ₹0.08 M | Satisfied |
How Many Employees Work at Gabreal Pharmaceuticals?
Unlock and access historical data on people associated with Gabreal Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Gabreal Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Gabreal Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.